Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17851417 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | June 2022 | January 2023 | Allow | 60 | 0 | 0 | Yes | No |
| 17255776 | ANTIBODIES FOR THE TREATMENT OF SYNUCLEINOPATHIES AND NEUROINFLAMMATION | December 2020 | July 2022 | Allow | 19 | 1 | 0 | Yes | No |
| 17127719 | ANTI-TRANSTHYRETIN ANTIBODIES | December 2020 | September 2022 | Allow | 21 | 0 | 0 | Yes | No |
| 17111159 | ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF | December 2020 | September 2022 | Allow | 21 | 0 | 0 | Yes | No |
| 17104344 | Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 Modulators | November 2020 | December 2023 | Abandon | 37 | 2 | 1 | No | No |
| 16951012 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | November 2020 | August 2024 | Abandon | 45 | 3 | 1 | Yes | No |
| 17097457 | AGENT, USES AND METHODS FOR TREATMENT | November 2020 | August 2022 | Allow | 21 | 0 | 0 | No | No |
| 17072946 | REGENERATING FUNCTIONAL NEURONS FOR TREATMENT OF NEUROLOGICAL DISORDERS | October 2020 | April 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17073242 | IDENTIFICATION OF SPATIAL BIOMARKERS OF BRAIN DISORDERS AND METHODS OF USING THE SAME | October 2020 | June 2024 | Abandon | 44 | 2 | 1 | No | No |
| 17068403 | DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERS | October 2020 | July 2024 | Abandon | 45 | 2 | 1 | No | No |
| 17033047 | TAU KINETIC MEASUREMENTS | September 2020 | October 2024 | Abandon | 48 | 1 | 0 | No | No |
| 17025241 | METHODS FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE | September 2020 | November 2023 | Allow | 37 | 1 | 1 | No | No |
| 17023963 | HUMANIZED ANTI-TAU(PS422) ANTIBODIES AND METHODS OF USE | September 2020 | November 2022 | Allow | 26 | 1 | 0 | Yes | No |
| 17006670 | B7-H4 ANTIBODIES AND METHODS AND USE THEREOF | August 2020 | November 2023 | Allow | 39 | 0 | 0 | Yes | No |
| 17003153 | ENZYMATIC MODIFICATION OF ANTI-AQP4 AUTOANTIBODY FOR MODULATING NEUROMYELITIS OPTICA | August 2020 | November 2023 | Abandon | 39 | 2 | 0 | No | No |
| 16987831 | Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals | August 2020 | May 2024 | Abandon | 45 | 2 | 2 | No | No |
| 16983185 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFLAMMATION | August 2020 | December 2022 | Allow | 28 | 1 | 0 | Yes | No |
| 16965676 | ANTI-MS4A4A ANTIBODIES AND METHODS OF USE THEREOF | July 2020 | June 2022 | Allow | 23 | 1 | 1 | Yes | No |
| 16965675 | ANTI-MS4A6A ANTIBODIES AND METHODS OF USE THEREOF | July 2020 | May 2022 | Abandon | 21 | 0 | 1 | No | No |
| 16941454 | TPP-1 Formulations and Methods for Treating CLN2 Disease | July 2020 | September 2021 | Allow | 13 | 0 | 0 | Yes | No |
| 16965565 | BINDING MOLECULES THAT SPECIFICALLY BIND TO TAU | July 2020 | October 2021 | Allow | 15 | 1 | 0 | Yes | No |
| 16929994 | ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES | July 2020 | December 2021 | Abandon | 17 | 1 | 1 | No | No |
| 16954187 | INDUCED COMMON ANTIBODY RESPONSE | July 2020 | October 2024 | Abandon | 52 | 1 | 1 | No | No |
| 16917330 | BLOCKADE OF TIM-1 PATHWAYS and P-SELECTIN PATHWAYS IN TREATMENT OF NEUROINFLAMMATORY DEGENERATIVE DISEASE | June 2020 | December 2022 | Abandon | 29 | 1 | 1 | No | No |
| 16959081 | ANTI-TMEM106B ANTIBODIES AND METHODS OF USE THEREOF | June 2020 | April 2022 | Allow | 22 | 1 | 1 | Yes | No |
| 16910058 | ANTIBODY FOR USE IN DETECTING EARLY-STAGE DAMAGE OF BLOOD BRAIN BARRIER DURING CEREBRAL ISCHEMIC STROKE AND APPLICATION THEREOF | June 2020 | August 2023 | Abandon | 38 | 2 | 1 | No | No |
| 16907296 | ANTIBODY FOR DETECTING EARLY DAMAGE OF BLOOD-BRAIN BARRIER IN ISCHEMIC STROKE AND APPLICATION THEREOF | June 2020 | August 2023 | Abandon | 38 | 2 | 1 | No | No |
| 16956369 | Tumstatin Assay | June 2020 | January 2023 | Abandon | 31 | 1 | 1 | No | No |
| 16905292 | METHODS AND COMPOSITIONS FOR INCREASING ENZYME ACTIVITY IN THE CNS | June 2020 | October 2022 | Abandon | 28 | 2 | 0 | No | No |
| 16955751 | ANTIBODIES TO CENTRIN-1, METHODS OF MAKING, AND USES THEREOF | June 2020 | March 2022 | Allow | 21 | 0 | 1 | Yes | No |
| 16895970 | ANTIBODIES TO DISULFATED HEPARIN DISACCHARIDE IN THE DIAGNOSIS OF NEUROPATHY | June 2020 | September 2022 | Abandon | 27 | 2 | 0 | No | No |
| 16768577 | MATERIALS AND METHODS INCLUDING FOR SEX SELECTION | May 2020 | August 2024 | Abandon | 51 | 0 | 1 | No | No |
| 16767979 | Activity Modulator | May 2020 | August 2022 | Abandon | 27 | 1 | 0 | No | No |
| 16883624 | EXOSOMAL TAU AS A BIOMARKER FOR BRAIN DISORDERS | May 2020 | November 2022 | Abandon | 30 | 0 | 1 | No | No |
| 16879286 | Treatment and Prophylaxis of Amyloidosis | May 2020 | October 2022 | Abandon | 29 | 1 | 0 | No | No |
| 16877103 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMYELITIS OPTICA | May 2020 | March 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 16869618 | ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES | May 2020 | August 2021 | Allow | 16 | 0 | 0 | Yes | No |
| 16869344 | HUMAN ANTIBODIES AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASE | May 2020 | July 2022 | Abandon | 27 | 3 | 0 | No | No |
| 16762141 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF HUMANIZED CONFORMATION-SPECIFIC PHOSPHORYLATED TAU ANTIBODIES | May 2020 | October 2022 | Allow | 29 | 1 | 1 | Yes | No |
| 16760390 | TREATMENT OF DISORDERS | April 2020 | May 2022 | Abandon | 25 | 1 | 1 | No | No |
| 16856855 | ANTIBODIES RECOGNIZING ALPHA-SYNUCLEIN | April 2020 | August 2020 | Allow | 3 | 0 | 0 | Yes | No |
| 16856407 | METHODS AND COMPOSITIONS FOR TREATING VIRUS-ASSOCIATED INFLAMMATION | April 2020 | June 2021 | Allow | 14 | 0 | 0 | Yes | No |
| 16852508 | Modified anti-PD-L1 Antibody and Methods and Uses for Treating a Neurodegenerative Disease | April 2020 | December 2020 | Allow | 8 | 1 | 0 | Yes | No |
| 16756960 | COMBINATION THERAPIES FOR TREATING BIPOLAR DISORDER AND ADHD, AND METHODS FOR USING THE SAME | April 2020 | November 2023 | Abandon | 43 | 1 | 1 | No | No |
| 16846210 | GENE THERAPIES FOR LYSOSOMAL DISORDERS | April 2020 | October 2023 | Allow | 42 | 2 | 1 | Yes | No |
| 16841539 | GENE THERAPIES FOR LYSOSOMAL DISORDERS | April 2020 | November 2022 | Allow | 31 | 1 | 0 | No | No |
| 16753671 | A SPECIFIC BINDING MOLECULE DIRECTED AGAINST GALECTIN-3 PROTEIN | April 2020 | May 2021 | Allow | 14 | 0 | 0 | Yes | No |
| 16839009 | NANOBODIES SUITABLE FOR NEURON REGENERATION THERAPY | April 2020 | February 2022 | Allow | 22 | 0 | 1 | Yes | No |
| 16828557 | FUSION PROTEINS FOR DELIVERY OF GDNF TO THE CNS | March 2020 | November 2022 | Abandon | 32 | 4 | 0 | No | No |
| 16822906 | TAU PROTEASE COMPOSITIONS AND METHODS OF USE | March 2020 | March 2024 | Allow | 48 | 2 | 0 | No | No |
| 16810422 | TREATMENT OF OCULAR DISEASES WITH HUMAN POST-TRANSLATIONALLY MODIFIED VEGF-TRAP | March 2020 | August 2024 | Abandon | 53 | 2 | 1 | No | No |
| 16808611 | INHIBITION OF SEMA3A IN THE PREVENTION AND TREATMENT OF OCULAR HYPERPERMEABILITY | March 2020 | October 2021 | Allow | 19 | 2 | 0 | No | No |
| 16808209 | ANTIBODIES RECOGNIZING TAU | March 2020 | December 2020 | Allow | 10 | 0 | 0 | Yes | No |
| 16641160 | ANTIBODIES USEFUL IN CANCER DIAGNOSIS | February 2020 | August 2021 | Allow | 17 | 0 | 1 | Yes | No |
| 16640073 | METHOD FOR PURIFYING PROTEINS | February 2020 | December 2023 | Abandon | 46 | 2 | 1 | No | No |
| 16795479 | Humanized Antibodies That Recognize Alpha-Synuclein | February 2020 | August 2020 | Allow | 6 | 0 | 0 | Yes | No |
| 16639808 | ANTI-APELIN ANTIBODIES AND USES THEREOF | February 2020 | April 2022 | Allow | 26 | 2 | 1 | Yes | No |
| 16791984 | NOVEL BIOMARKERS FOR COGNITIVE IMPAIRMENT AND METHODS FOR DETECTING COGNITIVE IMPAIRMENT USING SUCH BIOMARKERS | February 2020 | December 2021 | Allow | 22 | 2 | 0 | Yes | No |
| 16789738 | SP35 Antibodies And Uses Thereof | February 2020 | May 2021 | Abandon | 15 | 1 | 0 | Yes | No |
| 16784020 | ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF | February 2020 | October 2020 | Allow | 8 | 1 | 0 | Yes | No |
| 16782654 | METHODS OF TREATING ALZHEIMER'S DISEASE | February 2020 | December 2020 | Abandon | 11 | 1 | 0 | No | No |
| 16635943 | ANTIBODY BINDING ACTIVE ALPHA-SYNUCLEIN | January 2020 | April 2021 | Allow | 14 | 0 | 0 | Yes | No |
| 16632289 | ANTI- ISOASP7 AMYLOID ß (Aß) ANTIBODIES AND USES THEREOF | January 2020 | March 2023 | Allow | 38 | 1 | 1 | Yes | No |
| 16738542 | Intranasal Delivery of Cell Permeant Therapeutics | January 2020 | November 2021 | Abandon | 22 | 2 | 0 | No | No |
| 16628975 | NOVEL ANTI-HUMAN CEACAM5 ANTIBODY FAB FRAGMENT | January 2020 | January 2023 | Allow | 37 | 1 | 1 | Yes | No |
| 16625278 | FUSION PROTEIN | December 2019 | January 2023 | Abandon | 37 | 3 | 1 | Yes | No |
| 16622527 | COMPOSITIONS FOR INCREASING RESILIENCE TO TRAUMATIC BRAIN INJURY | December 2019 | August 2021 | Abandon | 20 | 1 | 0 | No | No |
| 16712525 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES | December 2019 | January 2022 | Abandon | 26 | 1 | 1 | No | No |
| 16621928 | PHOSPHO-RAB ANTIBODIES, ASSAYS AND METHODS OF USE THEREOF | December 2019 | January 2023 | Allow | 37 | 2 | 1 | Yes | No |
| 16619439 | NECTIN-4 BINDING PROTEINS AND METHODS OF USE THEREOF | December 2019 | August 2021 | Allow | 20 | 0 | 0 | Yes | No |
| 16616832 | EPITOPES IN THE RNA RECOGNITION MOTIF 1 (RRM1) OF TDP-43 AND MISFOLDING-SELECTIVE ANTIBODIES THERETO | November 2019 | September 2021 | Allow | 22 | 1 | 1 | Yes | No |
| 16692382 | METHODS AND COMPOSITIONS FOR EVALUATION AND TREATMENT OF SYNUCLEINOPATHIES | November 2019 | November 2021 | Abandon | 24 | 0 | 1 | No | No |
| 16692236 | ANTI-PACAP ANTIBODY | November 2019 | December 2020 | Allow | 13 | 0 | 0 | Yes | No |
| 16691578 | POLYPEPTIDE FOR TREATING PATHOLOGICAL BLOOD CLOTS | November 2019 | November 2021 | Allow | 24 | 1 | 1 | No | No |
| 16615201 | NEUROTROPHINS FOR USE IN THE TREATMENT OF HEARING LOSS | November 2019 | August 2022 | Abandon | 32 | 3 | 0 | No | No |
| 16611678 | ANTI-CLDN-5 ANTIBODY, AND DRUG CONTAINING SAID ANTIBODY | November 2019 | March 2021 | Allow | 16 | 0 | 1 | Yes | No |
| 16672899 | OPTOGENETIC THERAPEUTIC AND METHOD OF TREATING RETINAL DEGENERATIVE AND NEURODEGENERATIVE DISEASES | November 2019 | October 2021 | Abandon | 23 | 1 | 0 | No | No |
| 16669375 | ANTI-TRANSTHYRETIN ANTIBODIES | October 2019 | September 2020 | Allow | 11 | 0 | 0 | Yes | No |
| 16606220 | BINDING MOLECULE SPECIFIC FOR LRIG-1 PROTEIN AND USE THEREOF | October 2019 | November 2021 | Allow | 25 | 1 | 0 | Yes | No |
| 16498780 | NEW TAU SPECIES | September 2019 | November 2022 | Abandon | 38 | 3 | 1 | Yes | No |
| 16584634 | ANTI-TRANSTHYRETIN ANTIBODIES | September 2019 | February 2021 | Allow | 16 | 0 | 1 | Yes | No |
| 16497055 | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES | September 2019 | October 2021 | Abandon | 24 | 1 | 0 | No | No |
| 16496177 | HUMANIZED ANTI-NUCLEAR ANTIBODIES FOR TARGETING NECROSIS IN CANCER THERAPY | September 2019 | March 2022 | Allow | 29 | 0 | 1 | Yes | No |
| 16576249 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | September 2019 | February 2021 | Abandon | 17 | 1 | 0 | Yes | No |
| 16572271 | HUMAN PAC1 ANTIBODIES | September 2019 | May 2020 | Allow | 8 | 0 | 0 | Yes | No |
| 16494441 | Collagen Type XVIII Assay | September 2019 | January 2023 | Abandon | 40 | 1 | 1 | No | No |
| 16491675 | ANTI-C5 ANTIBODIES AND USES THEREOF | September 2019 | October 2022 | Allow | 37 | 3 | 0 | Yes | No |
| 16552498 | PSILOCYBIN COMPOSITIONS | August 2019 | February 2023 | Allow | 42 | 4 | 0 | Yes | No |
| 16484962 | ANTI-FACTOR D ANTIBODIES AND USES THEREOF | August 2019 | April 2022 | Allow | 32 | 2 | 1 | Yes | No |
| 16530551 | ANTIBODIES RECOGNIZING MEDIN | August 2019 | March 2021 | Abandon | 19 | 1 | 0 | Yes | No |
| 16521279 | AGENT, USES AND METHODS FOR TREATMENT | July 2019 | May 2020 | Allow | 10 | 0 | 0 | Yes | No |
| 16506639 | IDENTIFICATION AND ANALYSIS OF PROTEIN BIOMARKERS | July 2019 | July 2023 | Allow | 48 | 4 | 1 | Yes | No |
| 16503740 | COMBINATION THERAPY WITH CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES | July 2019 | June 2022 | Abandon | 35 | 2 | 0 | No | No |
| 16475299 | ANTIBODIES SPECIFIC FOR HYPERPHOSPHORLATED TAU FOR THE TREATMENT OF OCULAR DISEASES | July 2019 | December 2020 | Allow | 18 | 1 | 0 | Yes | No |
| 16474040 | METHODS FOR THE DETECTION OF TAU PROTEIN AGGREGATES | June 2019 | June 2023 | Allow | 48 | 4 | 1 | Yes | Yes |
| 16473413 | Anti-Claudin-2 Monoclonal Antibody | June 2019 | March 2021 | Allow | 21 | 0 | 0 | Yes | No |
| 16472816 | ALPHA-B CRYSTALLIN IN THE DIAGNOSIS OF NEONATAL BRAIN DAMAGE | June 2019 | February 2023 | Abandon | 44 | 5 | 0 | No | Yes |
| 16471730 | Motor Control Function Improving Agent | June 2019 | March 2022 | Allow | 33 | 2 | 1 | Yes | No |
| 16447093 | IN VITRO GLYCOENGINEERING OF ANTIBODIES | June 2019 | May 2023 | Abandon | 47 | 2 | 1 | No | No |
| 16470804 | ANTIBODY FRAMEWORKS FOR REDUCING AGGREGATION OF MULTISPECIFIC ANTIBODIES | June 2019 | November 2023 | Abandon | 52 | 3 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FONTAINHAS, AURORA M.
With a 35.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 14.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner FONTAINHAS, AURORA M works in Art Unit 1649 and has examined 463 patent applications in our dataset. With an allowance rate of 41.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 29 months.
Examiner FONTAINHAS, AURORA M's allowance rate of 41.3% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by FONTAINHAS, AURORA M receive 2.19 office actions before reaching final disposition. This places the examiner in the 56% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by FONTAINHAS, AURORA M is 29 months. This places the examiner in the 62% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +57.7% benefit to allowance rate for applications examined by FONTAINHAS, AURORA M. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 13.9% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 16.8% of cases where such amendments are filed. This entry rate is in the 21% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 71.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 60% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 56.4% of appeals filed. This is in the 29% percentile among all examiners. Of these withdrawals, 54.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 68.8% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.